Guide

UKCA medical device transition: the post-Brexit UK device compliance stack

UK medical device regulation operates under the Medical Devices Regulations 2002 (UK MDR 2002) as amended post-Brexit. The original UK MDR 2002 transposed the EU MDD 93/42/EEC, IVDD 98/79/EC and AIMDD 90/385/EEC. Post-Brexit, the UK established the UKCA mark as the UK conformity assessment route, with the UK(NI) mark for Northern Ireland (which continues to follow EU MDR 2017/745 and IVDR 2017/746 under the Windsor Framework). Critical transition dates have been extended multiple times: CE-marked devices compliant with EU MDR/IVDR remain accepted for placing on the GB market until June 30, 2030 (general medical devices and IVDs); CE-marked devices compliant with the legacy EU MDD/AIMDD accepted until June 30, 2028; CE-marked devices compliant with legacy IVDD accepted until June 30, 2030. MHRA is consulting on the future UK Medical Devices Regulations (UK MDR Reform) — first statutory instrument on post-market surveillance came into force June 2024, with broader reform expected through 2025-2026. Manufacturers register devices via the Device Online Registration System (DORS) with a UK Responsible Person required for non-UK manufacturers.

Start free trial Free trial, no credit card, onboard in days, not months.

The UK device stack — UKCA, CE acceptance, UK(NI), DORS, UK Responsible Person

Layer 0 is statutory framework: Medical Devices Regulations 2002 as amended post-Brexit, the Medical Devices (Northern Ireland Protocol) Regulations 2021 (Windsor Framework), and forthcoming UK MDR Reform statutory instruments. Layer 1 is conformity assessment route: UKCA mark via UK Approved Body (for Class IIa/IIb/III and IVDs requiring third-party review) or self-declaration (Class I non-sterile/non-measuring); UK(NI) mark requires EU Notified Body conformity assessment under EU MDR/IVDR per Windsor Framework. Layer 2 is CE acceptance — CE-marked devices compliant with EU MDR/IVDR are accepted on the GB market through June 30, 2030 (general devices and IVDs); legacy MDD/AIMDD CE marks accepted through June 30, 2028; legacy IVDD CE marks accepted through June 30, 2030. Layer 3 is MHRA registration — every device placed on the GB market must be registered via DORS with a UK Responsible Person for non-UK manufacturers, regardless of conformity assessment route. Layer 4 is post-market surveillance under the new June 2024 PMS regulations.

UKCA vs CE acceptance — choosing the route

Until June 30, 2030 (general MD and IVD compliant with EU MDR/IVDR), manufacturers can place devices on the GB market via CE marking — no UKCA mark required. This is the dominant practical choice for manufacturers already pursuing EU MDR/IVDR. After the cliff-edge date (or the earlier 2028 date for legacy MDD/AIMDD), UKCA marking becomes mandatory for GB market access. UKCA conformity assessment is done by UK Approved Bodies — currently a small set (BSI, TUV SUD, DEKRA UK, SGS UK, Lloyd's Register Quality Assurance). For UK(NI) market access, EU MDR/IVDR conformity assessment by an EU Notified Body remains required regardless of UKCA — Northern Ireland follows EU device law per the Windsor Framework. Manufacturers serving both GB and NI typically pursue EU MDR/IVDR via EU NB (covers EU + NI) plus UKCA when the CE acceptance ends (covers GB) — a dual conformity assessment burden.

MHRA registration via DORS

All medical devices placed on the GB market must be registered with MHRA via the Device Online Registration System (DORS), regardless of conformity assessment route. Registration requires: manufacturer details, UK Responsible Person details (for non-UK manufacturers), GMDN (Global Medical Device Nomenclature) code, device classification, conformity assessment basis (UKCA self-declaration, UKCA via Approved Body, CE via Notified Body), Notified Body number, and basic UDI-DI where applicable. UK Responsible Person obligations: hold the technical documentation, maintain the registration, cooperate with MHRA inquiries, vigilance reporting via MORE portal, post-market surveillance liaison. UK Responsible Person liability is shared with the manufacturer for non-conformities. Registration fee per device class; small-manufacturer concession available. Registration is per device, not per SKU — variants and accessories under the same intended purpose typically share a registration.

UK MDR Reform — June 2024 PMS regulations and the wider reform

MHRA's UK MDR Reform programme is delivered through phased statutory instruments. The first SI — the Medical Devices (Post-market Surveillance Requirements) Amendment Regulations 2024 — came into force June 2025 and brings UK PMS broadly into alignment with EU MDR Articles 83-86: PMS plan, PMS report (Class I), Periodic Safety Update Report (PSUR) for Class IIa/IIb/III, vigilance reporting with serious incident definitions, trend reporting. Future reform expected to address: pre-market conformity assessment harmonisation, in vitro diagnostic device classification, IUD-DI/UDI implementation, software as a medical device (SaMD) and AI/ML medical device pathway, custom-made and patient-matched devices, clinical investigation reform. The reform broadly tracks EU MDR/IVDR principles with UK-specific divergence including potential international recognition pathways (FDA, Health Canada, Australia TGA, Japan PMDA).

Northern Ireland under the Windsor Framework

Northern Ireland continues to follow EU MDR 2017/745 and IVDR 2017/746 for devices placed on the NI market, under the Windsor Framework. UK(NI) mark applies for devices conformity-assessed by UK Approved Bodies operating with EU NB recognition (limited applicability) — practical effect is that NI device market access requires EU NB conformity assessment with CE mark. Devices placed on the NI market by GB-based manufacturers travelling through GB must satisfy the Windsor Framework movement rules, with green-lane and red-lane procedures and the UK Internal Market Scheme (UKIMS) registration. Vigilance for NI-placed devices goes to MHRA but with EU-level coordination. UK Responsible Person registers GB market; EU Authorised Representative (often in Ireland) covers EU + NI market.

Practical readiness — building for the UK device stack

For each device, document the GB market route (UKCA self-declaration, UKCA via Approved Body, or CE acceptance through 2028/2030) with the underlying conformity assessment basis. Appoint a UK Responsible Person if non-UK manufacturer and register devices in DORS. Maintain a current technical file accessible to the UK Responsible Person. Implement the June 2025 PMS regulations with PMS plan, PMS report or PSUR per classification, and vigilance reporting via MHRA MORE. Plan the CE-to-UKCA transition ahead of the 2028/2030 cliff edges — UK Approved Body capacity is limited and conformity assessment lead times are long. For NI market access, maintain EU MDR/IVDR conformity assessment via EU Notified Body. Track UK MDR Reform statutory instruments through 2025-2026 — the reform will materially change pre-market and SaMD/AI pathways.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Industries this hits hardest

Medical devices Blood, tissue & cell therapy Pharmaceutical

Frequently asked

Do I need a UKCA mark if I have a CE mark under EU MDR?

Not until the cliff-edge date. CE-marked devices compliant with EU MDR/IVDR are accepted on the GB market through June 30, 2030 (general MD and IVD). Legacy MDD/AIMDD CE marks are accepted through June 30, 2028. Plan UKCA transition with conformity-assessment lead time well before the cliff edge.

Is the UK Responsible Person the same as an EU Authorised Representative?

Functionally similar but legally distinct. UK Responsible Person is the UK-based representative required for non-UK manufacturers placing devices on the GB market. EU Authorised Representative is the EU-based representative under EU MDR/IVDR. Many manufacturers appoint both for the respective markets — they share documentation but are separate legal appointments.

How does MHRA vigilance reporting work?

Serious incidents and field safety corrective actions are reported to MHRA via the MORE (Manufacturer's On-line Reporting Environment) portal. Reporting timelines aligned with EU MDR (2 days for serious public health threats, 10 days for death/serious deterioration, 15 days otherwise). UK Responsible Person can submit on the manufacturer's behalf. Trend reports for statistically significant increases per the June 2025 PMS regulations.

Can I use an FDA 510(k) for UK market entry?

Not directly. UK Approved Body conformity assessment uses UK-relevant Essential Requirements (substantially aligned to MDD Essential Requirements) and may consider FDA clearance as supporting evidence but does not recognise FDA 510(k) as conformity assessment. MHRA is consulting on International Recognition Procedure for medical devices similar to the medicines IRP — implementation expected post-2026.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →